Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen

Luigi Aurisicchio, Giuseppe Roscilli, Emanuele Marra, Laura Luberto, Rita Mancini, Nicola La Monica, Gennaro Ciliberto

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We have generated a xenogeneic vaccine against human carcinoembryonic antigen (hCEACAM-5 or commonly hCEA) using as immunogen rhesus CEA (rhCEA). RhCEA cDNA was codon-usage optimized (rhCEAopt) and delivered by sequential DNA electro-gene-transfer (DNA-EGT) and adenoviral (Ad) vector. RhCEAopt was capable to break tolerance to CEA in hCEA transgenic mice and immune responses were detected against epitopes distributed over the entire length of the protein. Xenovaccination with rhCEA resulted in the activation of CD4+ T-cell responses in addition to self-reactive CD8+ T-cells, the development of high-titer antibodies against hCEA, and significant antitumor effects upon challenge with hCEA+ tumor cells. The superior activity of rhCEAopt compared with hCEAopt was confirmed in hCEA/HHD double-transgenic mice, where potent CD8+ T-cell responses against specific human HLA A∗0201 hCEA epitopes were detected. Our data show that xenogeneic gene-based vaccination with rhCEA is a viable approach to break tolerance against CEA, thus suggesting further development in the clinical setting.

Original languageEnglish
Pages (from-to)386-398
Number of pages13
JournalHuman Gene Therapy
Volume26
Issue number6
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Cancer Vaccines
Carcinoembryonic Antigen
T-Lymphocytes
Transgenic Mice
Epitopes
Codon
Genes
Vaccination
Therapeutics
Vaccines
Complementary DNA
Antibodies
DNA
Neoplasms
Proteins

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen. / Aurisicchio, Luigi; Roscilli, Giuseppe; Marra, Emanuele; Luberto, Laura; Mancini, Rita; La Monica, Nicola; Ciliberto, Gennaro.

In: Human Gene Therapy, Vol. 26, No. 6, 01.06.2015, p. 386-398.

Research output: Contribution to journalArticle

Aurisicchio, Luigi ; Roscilli, Giuseppe ; Marra, Emanuele ; Luberto, Laura ; Mancini, Rita ; La Monica, Nicola ; Ciliberto, Gennaro. / Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen. In: Human Gene Therapy. 2015 ; Vol. 26, No. 6. pp. 386-398.
@article{ff16a0a8b9da4ca38f01fb87782edb5a,
title = "Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen",
abstract = "We have generated a xenogeneic vaccine against human carcinoembryonic antigen (hCEACAM-5 or commonly hCEA) using as immunogen rhesus CEA (rhCEA). RhCEA cDNA was codon-usage optimized (rhCEAopt) and delivered by sequential DNA electro-gene-transfer (DNA-EGT) and adenoviral (Ad) vector. RhCEAopt was capable to break tolerance to CEA in hCEA transgenic mice and immune responses were detected against epitopes distributed over the entire length of the protein. Xenovaccination with rhCEA resulted in the activation of CD4+ T-cell responses in addition to self-reactive CD8+ T-cells, the development of high-titer antibodies against hCEA, and significant antitumor effects upon challenge with hCEA+ tumor cells. The superior activity of rhCEAopt compared with hCEAopt was confirmed in hCEA/HHD double-transgenic mice, where potent CD8+ T-cell responses against specific human HLA A∗0201 hCEA epitopes were detected. Our data show that xenogeneic gene-based vaccination with rhCEA is a viable approach to break tolerance against CEA, thus suggesting further development in the clinical setting.",
author = "Luigi Aurisicchio and Giuseppe Roscilli and Emanuele Marra and Laura Luberto and Rita Mancini and {La Monica}, Nicola and Gennaro Ciliberto",
year = "2015",
month = "6",
day = "1",
doi = "10.1089/hum.2014.141",
language = "English",
volume = "26",
pages = "386--398",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen

AU - Aurisicchio, Luigi

AU - Roscilli, Giuseppe

AU - Marra, Emanuele

AU - Luberto, Laura

AU - Mancini, Rita

AU - La Monica, Nicola

AU - Ciliberto, Gennaro

PY - 2015/6/1

Y1 - 2015/6/1

N2 - We have generated a xenogeneic vaccine against human carcinoembryonic antigen (hCEACAM-5 or commonly hCEA) using as immunogen rhesus CEA (rhCEA). RhCEA cDNA was codon-usage optimized (rhCEAopt) and delivered by sequential DNA electro-gene-transfer (DNA-EGT) and adenoviral (Ad) vector. RhCEAopt was capable to break tolerance to CEA in hCEA transgenic mice and immune responses were detected against epitopes distributed over the entire length of the protein. Xenovaccination with rhCEA resulted in the activation of CD4+ T-cell responses in addition to self-reactive CD8+ T-cells, the development of high-titer antibodies against hCEA, and significant antitumor effects upon challenge with hCEA+ tumor cells. The superior activity of rhCEAopt compared with hCEAopt was confirmed in hCEA/HHD double-transgenic mice, where potent CD8+ T-cell responses against specific human HLA A∗0201 hCEA epitopes were detected. Our data show that xenogeneic gene-based vaccination with rhCEA is a viable approach to break tolerance against CEA, thus suggesting further development in the clinical setting.

AB - We have generated a xenogeneic vaccine against human carcinoembryonic antigen (hCEACAM-5 or commonly hCEA) using as immunogen rhesus CEA (rhCEA). RhCEA cDNA was codon-usage optimized (rhCEAopt) and delivered by sequential DNA electro-gene-transfer (DNA-EGT) and adenoviral (Ad) vector. RhCEAopt was capable to break tolerance to CEA in hCEA transgenic mice and immune responses were detected against epitopes distributed over the entire length of the protein. Xenovaccination with rhCEA resulted in the activation of CD4+ T-cell responses in addition to self-reactive CD8+ T-cells, the development of high-titer antibodies against hCEA, and significant antitumor effects upon challenge with hCEA+ tumor cells. The superior activity of rhCEAopt compared with hCEAopt was confirmed in hCEA/HHD double-transgenic mice, where potent CD8+ T-cell responses against specific human HLA A∗0201 hCEA epitopes were detected. Our data show that xenogeneic gene-based vaccination with rhCEA is a viable approach to break tolerance against CEA, thus suggesting further development in the clinical setting.

UR - http://www.scopus.com/inward/record.url?scp=84932602354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84932602354&partnerID=8YFLogxK

U2 - 10.1089/hum.2014.141

DO - 10.1089/hum.2014.141

M3 - Article

AN - SCOPUS:84932602354

VL - 26

SP - 386

EP - 398

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 6

ER -